Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
961-980 of 998 trials

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePulmonology

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Major Depressive Disorder: NBI-1065845 Treatment Study

We are evaluating a new medication to see if it helps maintain improvement in people with Major Depressive Disorder. This study looks at its effects on depressive symptoms and overall functioning.

Major Depressive DisorderConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Ulcerative Colitis: RO7837195 Treatment Study

We are testing a new medication, RO7837195, for people with moderately to severely active ulcerative colitis. The study aims to see if it can help induce remission and how safe it is compared to a placebo.

Ulcerative Colitis>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Ulcerative Colitis: SAR441566 Study

We are investigating the effects of SAR441566 in adults with moderate-to-severe ulcerative colitis. The study aims to see if different doses can help achieve remission and improve overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Primary Aldosteronism: Baxdrostat Study

We are investigating how safe and effective baxdrostat is for adults with primary aldosteronism. The goal is to see if it can improve blood pressure and other health measures compared to a placebo.

Primary Hyperaldosteronism1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Inflammatory Rheumatic Diseases: JAK Inhibitor Dose Reduction Study

We are exploring if lowering the dose of JAK inhibitors is as effective as keeping the current dose for patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis in low disease activity. This study will also look at safety and how many patients can successfully reduce their medication.

Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Idiopathic Hypersomnia: ALKS 2680 Study

We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Graves' Disease: Rilzabrutinib Study

We are investigating whether rilzabrutinib can help reduce thyroid activity in adults with Graves' disease. The study also aims to evaluate the safety of this new treatment.

Graves' Disease3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Darolutamide and Bipolar Androgen Therapy for Advanced Prostate Cancer

We are studying whether combining Darolutamide with bipolar androgen therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer compared to standard treatments.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Obesity Treatment: Orforglipron Tablet Study

We are investigating how well a new daily tablet helps people with obesity or overweight, both with and without type 2 diabetes, in reducing weight and improving blood sugar levels compared to a placebo.

ObesityOverweightType 2 Diabetes1-2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Ovarian Cancer: COM701 Treatment Study

We are testing the safety and effectiveness of COM701 for patients with relapsed platinum-sensitive ovarian cancer. The study aims to see if it can help patients maintain their health without cancer progression.

Ovarian CancerRecurrent Ovarian Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Chronic Subdural Hematoma: Timing of Anticoagulation

We are studying whether starting blood-thinning medication early or later helps patients with atrial fibrillation recover better after surgery for chronic subdural hematoma. This research looks at potential risks and overall health outcomes.

Chronic Subdural HematomaAtrial Fibrillation3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Type 2 Diabetes: Vicadrostat and Empagliflozin Study

We are testing the combination of vicadrostat and empagliflozin in people with type 2 diabetes, high blood pressure, and heart disease. The goal is to see if this combination can improve heart health compared to a placebo.

Type 2 DiabetesHypertensionCardiovascular Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine